News
We send the latest information from SMC Laboratories.
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimo…
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept …
SMC client receives award for presentation on study of NASH diagnosis at 40th annual meeting of JSLSM
Today, I would like to share with you some wonderful and exciting news! Recently, a client of ours from the Na…
Introduction of our Primary sclerosing cholangitis (PSC) mice model
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our…
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. &nb…
Drug Efficacy Study in the STAM™ Model Published in Cells
SMC is proud to announce that Cellaïon (BEL) has published the results of their study using our STAM&trad…
Drug Efficacy Study in the STAM™ Model Published in Gene
SMC is proud to announce that TSUMURA & CO. (JPN) has published the results of their study using our…
SMC participate The BioJapan Partnering!
We are pleased to announce that SMC Laboratories will be participating the BioJapan Partnering Event from…
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), a…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints u…